Photo by ricochet64/Shutterstock.com
The U.S. Court of Appeals for the Federal Circuit has just made it more difficult to sue generic drug makers for patent infringement in Delaware and New Jersey.
8 minute read
Thursday's ruling means fewer pharmaceuticals may bring Hatch-Waxman Act lawsuits in the popular venues of Delaware and New Jersey.
November 05, 2020 at 06:21 PM
1 minute read
The U.S. Court of Appeals for the Federal Circuit has just made it more difficult to sue generic drug makers for patent infringement in Delaware and New Jersey.
Presented by BigVoodoo
The National Law Journal Elite Trial Lawyers recognizes U.S.-based law firms performing exemplary work on behalf of plaintiffs.
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Breaking news and trends for law firm and legal departments about the evolving federal regulations in a volatile political climate.
